Double-Drug maintenance may extend remission in multiple myeloma

NCT ID NCT06461988

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether a combination of two drugs—talquetamab and lenalidomide—can help prevent multiple myeloma from returning after a stem cell transplant. The study enrolls 20 adults with symptomatic multiple myeloma who have already undergone a transplant. Participants receive talquetamab injections and lenalidomide pills for up to 13 cycles. The main goal is to see how many patients achieve a complete response (no detectable cancer) at 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: talquetamab and lenalidomide
What this could lead to: If successful, this combination could help keep multiple myeloma in remission longer after a stem cell transplant, potentially improving survival.
What could go wrong: This is a small, early-phase (phase 2) study with only 20 participants. The drugs may cause side effects, and the results may not apply to all myeloma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA POST STEM CELL TRANSPLANT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Stanford University
RECRUITING

Palo Alto, California, 94304, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.